Why Esther likes Amcor
Why Esther likes Amcor
About this video
Key points:
Amcor (ASX:AMC) trading at a 27% discount to fair value
Cyclical headwinds currently pressuring volumes and share price
Sustainability and healthcare segments provide growth opportunities
Recent Berry acquisition supports expansion in medical packaging
Morningstar’s Esther Holloway sees significant long-term potential in Amcor (ASX:AMC), the global packaging leader. Holloway identifies the stock as trading at a substantial 27% discount to her fair value estimate of $17.80, suggesting an appealing entry point for investors. She points to cyclical pressures, especially in the US and Europe, where volume declines are tied to weaker macroeconomic conditions and consumer shifts toward lower-cost goods. Holloway notes these factors have overshadowed Amcor’s prospects, with shares down about 18% over the past year.
Holloway outlines sector trends impacting Amcor, particularly a move towards environmental packaging as regulation and consumer sentiment drive innovation. European customers, in particular, are pushing changes like biodegradable packaging, with R&D investment central to Amcor’s strategy. She highlights growing opportunity in healthcare, following the recent acquisition of Berry, positioning Amcor to capitalise on increasing demand for medical packaging with higher margins and less competition.
Looking ahead, Holloway expects margins to benefit as Amcor’s healthcare segment expands, driven by the ageing population and greater medical needs. Holloway anticipates a recovery as household wealth improves, ultimately lifting demand for a wider range of packaged goods.